Tempest Therapeutics Earnings Call Transcripts
Fiscal Year 2024
-
Amezalpat, targeting PPAR-alpha, showed significant efficacy and safety in first-line liver cancer when combined with Tecentriq and Avastin, with benefits across key patient subgroups. A global Phase III trial is set to launch, with additional pipeline progress in renal cancer and FAP syndrome.
-
Positive phase 2 results for amezalpat in liver cancer showed a 35% reduction in risk of death and a six-month survival benefit, with broad FDA support for a phase 3 trial starting next year. The pipeline includes additional assets and expansion plans in other cancers.
-
Amezalpat plus atezolizumab/bevacizumab showed a six-month median OS improvement over standard care in first-line liver cancer, with a hazard ratio of 0.65 and consistent benefit across subgroups. The safety profile was manageable, and a phase III trial is planned with a three-year timeline.
-
A diversified oncology pipeline is advancing, with TPST-1120 showing strong phase II efficacy and safety in first-line liver cancer. A pivotal phase III trial is planned globally, with key OS data and FDA feedback expected soon.